Prediction of pharmacokinetic behaviour by combining in vivo and in vitro data in physiologically based pharmacokinetic (PBPK) model: Parameter estimation and sensitivity analysis

Journal of the Indian Institute of Science

Volumn 88, Issue 1, 2008, Pages 57-71

  Das, Debasish ^a   Dhurjati, Prasad ^b   Wangikar, Pramod P ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

^b University of Delaware   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL CULTURE; ARSENIC COMPOUNDS; CARDIOVASCULAR SYSTEM; COMPUTER NETWORKS; CONCENTRATION (PROCESS); ERROR ANALYSIS; FORECASTING; MATHEMATICAL MODELS; MOBILE TELECOMMUNICATION SYSTEMS; MODAL ANALYSIS; PARAMETER ESTIMATION; PHARMACOKINETICS; PROTEINS;

IN-VIVO;

SENSITIVITY ANALYSIS;

EID: 51549083399     PISSN: 09704140     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. M. Dickins, and H. van de Waterbeemd, "Simulation models for drug disposition and drug interactions", Drug Discovery Today: BIOSILICO, 2004, 2(1), 8-45.
2. K.B. Bischoff, and R.L. Dedrick, "Thiopental pharmacokinetics", Journal of Phamaceutical Science, 1968 57(8), 1346-1351.
3. S. Willmann, et al., "PK-Sim(R): a physiologically based pharmacokinetic 'whole-body' model", BIOSILICO, 2003, 1(4), 121-124.
4. F.P. Theil, T.W. Guentert, S. Haddad, and P. Poulin, "Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection", Toxicology Letters, 2003, 138, 29-49.
5. J.F. Young, "Physiologically-based pharmacokinetic model for pregnancy as a tool for investigation of developmental mechanisms", Computers in Biology and Medicine, 1998, 28, 359-364.
6. J. Rose, et al., "Development and validation of an advanced compartmental absorption and transit model:GastroPlusTM", In Proceedings of the Western Regional AAPS Meeting, 1998.
7. L.X. Yu, J.R. Crison, and G.L. Amidon, "Compartmental transit and dispersion model analysis of small intestinal transit flow in humans", International Journal of Pharmaceutics, 1996, 140, 111-118
8. H. M. Barham, M. S. Lennard, and G. T. Tucker, "An evaluation of Cytochrome-P450 isoform activities in the female dark Agouti (Da) rat - Relevance to its use as a model of the Cyp2d6 poor metabolizer phenotype", Biochemical Pharmacology, 1994, 47, 1295-1307.
9. M. S. Ching, C. L. Blake, H. Ghabrial, S. W. Ellis, M. S. Lennard, G. T. Tucker, and R. A. Smallwood, "Potent inhibition of yeast-expressed Cyp2d6 by dihydroquinidine, quinidine, and its metabolites", Biochemical Pharmacology, 1995, 50, 833-837.
10. G. T. Tucker, et al., "Genetic variability in pharmacokinetics", Development of Drugs and Modern Medicine, 1986, 462-473.
11. Y. Nishizato, I. Ieiri, H. Suzuki, M. Kimura, K. Kawabata, T. Hirota, H. Takane, S. Irie, H. Kusuhara, Y. Urasaki, A. Urae, S. Higuchi, K. Otsubo, and Y. Sugiyama, "Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics", Clinical Pharmacology & Therapeutics, 2003, 73, 554-565.
12. Barton, et al., "Characterizing uncertainty and variability in physiologically-based pharmacokinetic (PBPK) models: State of the science and needs for research and implementation", Toxicol. Sci., 2007, 99(2), 395-402.
13. R. P. Brown, M. D. Delp, S. L. Lindstedt, L. R. Rhomberg, and R. P. Beliles, " Physiological parameter values for physiologically based pharmacokinetic models", Toxicology and Industrial Health, 1997, 13, 407-484.
14. P. L. Bonate, A. Swann, and P. B. Silverman, "Preliminary physiologically based pharmacokinetic model for cocaine in the rat: Model development and scale-up to humans", Journal of Pharmaceutical Sciences, 1996, 85, 878-883.
15. K. Nezasa, K. Higaki, M. Takeuchi, M. Nakano, and M. Koike, "Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin", Xenobiotica, 2003, 33, 379-388.
16. W. Jacobsen, G. Kirchner, K. Hallensleben, L. Mancinelli, M. Deters, I. Hackbarth, L. Z. Benet, K. F. Sewing, and U. Christians, "Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver", Drug Metabolism and Disposition, 1999, 27, 173-179.
17. M. D. Morris, "Factorial sampling plans for preliminary computational experiments", Technometrics, 1991, 33(2), 161-174.
18. A. Saltelli, C. K., and E. M. Scott, Sensitivity Analysis, John Wiley 8i Sons Ltd., Chichester, England, 2001.
19. R. I. Cukier, H. B. Levine, and K. E. Shuler, "Nonlinear sensitivity analysis of multiparameter model systems", Journal of Computational Physics, 1978, 26, 1-42.
20. I. M. Sobol, "Sensitivity estimates for nonlinear mathematical models", Mathematical Modelling & Computational Experiment, 1993, 1, 407-414.
21. T. Komai, et al., "Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys", European Journal of Drug Metabolism and Pharmacokinetics, 1992, 17(2), 103-113.
22. M. Yamazaki, H. Suzuki, M. Hanano, T. Tokui, T. Komai, and Y. Sugiyama, "Na+-independent multispecific anion transporter mediates active-transport of Pravastatin into ratliver", American Journal of Physiology, 1993, 264, G36-G44.
23. M. Kakyo, H. Sakagami, T. Nishio, D. Nakai, R. Nakagomi, T. Tokui, T. Naitoh, S. Matsuno, T. Abe, and H. Yawo, 'Immunohistochemical distribution and functional characterization of an organic anion transporting polypeptide 2 (oatp2)", Febs Letters, 1999, 445, 343-346.
24. T. Tokui, D. Nakai, R. Nakagomi, H. Yawo, T. Abe, and Y. Sugiyama, "Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2", Pharmaceutical Research, 1999, 16, 904-908.
25. D. Nakai, R. Nakagomi, Y. Furuta, T. Tokui, T. Abe, T. Ikeda, and K. Nishimura, "Human liver-specific organic anion transporter, LST-1, mediates uptake of Pravastatin by rat hepatocytes", The Journal of Pharmacology and Experimental Therapeutics, 2001, 297, 861-867.
26. T. Abe, M. Kakyo, T. Tokui, R. Nakagomi, T. Nishio, D. Nakai, H. Nomura, M. Unno, M. Suzuki, T. Naitoh, S. Matsuno, and H. Yawo, "Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1 ", Journal of Biological Chemistry, 1999, 274, 17159-17163.
27. M. Yamazaki, S. Akiyama, K. Niinuma, R. Nishigaki, and Y. Sugiyama, "Biliary excretion of pravastatin in rats: Contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter (cMOAT)" Drug Metabolism and Disposition, 1997, 25, 1123-1129.
28. T. Mikkaichi, T. Suzuki, T. Onogawa, M. Tanemoto, H. Mizutamari, M. Okada, T. Chaki, S. Masuda, T. Tokui, N. Eto, M. Abe, F. Satoh, M. Unno, T. Hishinuma, K. Inui, S. Ito, I. Goto, and T. Abe, "Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney", Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3569-3574.
29. B. Noe, B. Hagenbuch, B. Stieger, and P. J. Meier, "Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain", Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 10346-10350.
30. T. Kodawara, S. Masuda, H. Wakasugi, Y. Uwai, T. Futami, H. Saito, T. Abe, and K. Inui, "Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone in the rat liver", Pharmaceutical Research, 2002, 19, 738-743.
31. Y. Shitara, D. Sugiyama, H. Kusuhara, Y. Kato, T. Abe, P. J. Meier, T. Itoh,and Y. Sugiyama, "Comparative inhibitory effects of different compounds on rat Oatp1 (Slc21a1)-and Oatp2 (Slc21a5)-mediated transport", Pharmaceutical Research, 2002, 19, 147-153.
32. I. De Lannoy et al., "The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin", Biochem. Biophys. Res. Commun., 1992, 189, 551-557.
33. Y. Y. Lau, C. Y. Wu, H. Okochi, and L. Z. Benet, "Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: Hepatic enzyme-transporter interplay", Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 1040-1045.
34. L. Harrison et al., "Pharmacokinetics of digoxin in the rat", Drug Metab. Dispos., 1976, 4, 88-93.
35. A. Schmoldt, et al.,: "Cleavage of digoxigenin digitoxosides by rat liver microsomes", Eur. J. Drug Metab. Pharmacokinet., 1980, 5, 225-23233.
36. S. Rodin, et al., "Pharmacokinetic interactions with digoxin", Clin. Pharmacokinet., 1998, 15, 227-244.
37. D. S. Wang, J. W. Jonker, Y. Kato, H. Kusuhara, A. H. Schinkel, and Y. Sugiyama, "Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin", Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 510-515.
38. M. Sugawara-Yokoo, et al., "Differential localization of organic cation transporters rOCT1 and rOCT2 in the basolateral membrane of rat kidney proximal tubules", Histochem. Cell biol., 2000, 114, 175-180.
39. X. Wu, et al., "Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney", Am. J. Physiol, 2000, 279, F449-F485.
40. R. Zwart, S. Verhaagh, M. Buitelaar, C. Popp-Snijders, D. P. Barlow, "Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice", Molecular and Cellular Biology, 2001, 21, 4188-4196.
41. G. Armayor, et al., "Lisinopril: a new angiotension- converting enzyme inhibitor", Drug Intelligence & Clinical Pharmacy, 1988, 22(5), 365-372.
42. K. Westphal, A. Weinbrenner, T. Giessmann, M. Stuhr, G. Franke, M. Zschiesche, R. Oertel, B. Terhaag, H. K. Kroemer, and W. Siegmund, "Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein", Clinical Pharmacology & Therapeutics, 2000, 68, 6-12.
43. R. Huupponen, et al., "Determination of metformin in plasma by high-performance liquid chromatography", Journal of Chromatography, 1992, 583, 270-273.
44. O. Sagirli, and L. Ersoy, "n HPLC method for the determination of lisinopril in human plasma and urine with fluorescence detection", Journal of Chromatography B - Analytical Technologies in the Biomedical and Life Sciences, 2004, 809, 159-165.
45. C. H. Oliveira, R. E. Barrientos-Astigarraga, M. Sucupira, G. S. Graudenz, M. N. Muscara, and G. De Nucci, "Quantification of methyldopa in human plasma by high-performance liquid chromatography-electrospray tandem mass spectrometry - Application to a bioequivalence study", Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, 2002, 768, 341-348.
46. D. E, Leahy, "Drug discovery information integration: virtual humans for pharmacokinetics", BIOSILICO, 2004, 2, 78-84.